Intuitive Surgical schedules Q3 results as Intuitive Surgical stock faces a 15.6 percent growth test

Published on 10/20/2026 at 10:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 consensus calls for USD 2.65 earnings per share on USD 2.91 billion revenue. Intuitive Surgical stock costs EUR 387.43 on October 20, 2026 before results.

Third quarter test and valuation

Intuitive Surgical expects third-quarter revenue of USD 2.91 billion on October 20, 2026.
Second-quarter revenue reached USD 2.89 billion, up 18.40 percent year over year.
Intuitive Surgical stock trades at EUR 387.43 at 10:42 a.m. CEST at Lang & Schwarz on October 20, 2026.
The company had a USD 153.0 billion market capitalization as of October 19, 2026.

Isometrische 3D-Illustration eines Operationssaals in 45-Grad-Ansicht mit Robotereinheit über OP-Tisch, Chirurgensteuerkonsole links, Monitorturm und Instrumententisch, pastell-türkises Farbschema — Intuitive Surgical US46120E6023 isometrische 3D Illustration zeigt vollständigen Roboter OP Saal mit Konsole, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) heads into its third-quarter report with consensus revenue of USD 2.91 billion and earnings per share of USD 2.65. The company is scheduled to report after the market close on October 20, 2026, with the call set for 4:30 p.m. ET, according to MarketBeat.

Expectations have moved higher

The revenue forecast implies 16.00 percent growth from USD 2.51 billion in the year-earlier quarter. Consensus earnings per share of USD 2.65 would be 10.42 percent above the prior-year figure of USD 2.40, giving the report a clear numerical hurdle.

Intuitive Surgical's second-quarter results provide the latest operating benchmark. On July 16, 2026, the company reported USD 2.80 earnings per share and USD 2.89 billion in revenue, while the consensus earnings estimate was USD 2.48, according to MarketBeat. Revenue was 18.40 percent higher than in the comparable period.

What will the report mean for margins

The key operating question is whether procedure growth can support profitability while adoption expands. Intuitive Surgical's investor page says the company develops and markets the da Vinci surgical system, and its latest outlook includes a 68 to 69 percent adjusted gross margin for 2026, as reported in a dated market overview from Boerse Express. That makes the combination of procedure growth and margin delivery more informative than revenue alone.

Three dated operating markers

On July 16, 2026, Intuitive Surgical reported USD 2.89 billion in second-quarter revenue and USD 2.80 earnings per share, according to MarketBeat. On September 8, 2026, the company highlighted a meta-analysis covering 13 benign conditions on its investor-relations page, Intuitive Surgical. The current event is the October 20, 2026 third-quarter report and conference call, listed on the same investor-relations page.

Dates investors can measure

October 20, 2026 is the reporting date, and the earnings conference call follows at 4:30 p.m. ET. The next measurable checkpoints are therefore the revenue result of USD 2.91 billion and earnings per share of USD 2.65 expected for the third quarter.

Valuation sets a second test

Intuitive Surgical's market capitalization was USD 153.0 billion as of October 19, 2026. Its primary listing is Nasdaq under ticker ISRG, while the USD 328.57 to USD 603.88 52-week range shows that the current valuation sits well below the year's high and above its low.

Intuitive Surgical was trading at EUR 387.43 at Lang & Schwarz on October 20, 2026 at 10:42 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.